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Clock proteins govern circadian physiology. We show that CK2α, corresponds to our 
previously reported kinase p45PFK, rhythmically phosphorylates clock protein BMAL1 in 
the suprachiasmatic nuclei, the mammalian central pacemaker. Gene silencing for CK2α 
and BMAL1 mutagenesis of a CK2-phosphorylation site (Ser90) result in impaired 
nuclear BMAL1 accumulation and subsequent disruption of clock function. These 
findings reveal that circadian rhythmic kinase CK2 is an essential regulator of the 
mammalian circadian system. 
 
 
The circadian clock orchestrates intrinsic timing in most organisms and controls a large 
variety of physiological and metabolic programs1. The molecular core of the circadian clock is 
constituted by a number of gene products that operate in transcriptional-translational feedback 
loops1, 2. The BMAL1-CLOCK heterodimer is central to the clock mechanism by binding to 
promoter E-box elements, driving and maintaining circadian oscillations3, 4. A common feature 
of clock proteins in various organisms is their rhythmic phosphorylation2, 5, 6. Various kinases 
have been implicated, whereas the Drosophila dCK2 specifically regulates the nuclear entry of 
dPER thereby controlling the fly clock 7.  
Periodically fluctuating kinases (PFKs) were originally described as clock-controlled 
enzymes in the rat suprachiasmatic nuclei (SCN) 8. Purification and characterization of p45PFK, 
the species displaying the highest fluctuation in enzymatic activity, indicated that it could 
function as a bona fide histone H1 and CLOCK kinase 8,9. To establish the identity of p45PFK, 
we performed a microsequencing analysis using Mass spectrometry (MS) on a highly 
gel-purified p45PFK from rat brain. The determined amino acid sequence revealed a complete 
match with rat CK2α (Supplementary Fig. 1). In a search of optimal clock targets for CK2α 
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(not shown), we found that purified p45PFK phosphorylates BMAL1 in vitro with the highest 
efficacy (Supplementary Fig. 2).  
 Based on these notions, we decided to explore whether CK2α would rhythmically 
phosphorylate BMAL1 in the SCN. To do so, we prepared CK2α-immunoprecipitates from 
both nuclear and cytoplasmic fractions isolated from rat SCN at various circadian times. The 
CK2α-immunoprecipitates were then used in kinase assays on BMAL1 as a substrate. A clear 
rhythmic pattern of BMAL1 phosphorylation is observed, particularly pronounced in the 
cytoplasmic fraction (Fig. 1A). Thus, CK2α functions as a circadian kinase, in accordance to 
the previously reported rhythmic activity of p45PFK 8. On the other hand, the kinase function of 
the Drosophila CK2 toward a CK2-phosphorylation motif peptide does not display a rhythmic 
activity 7. As the levels of all CK2 subunits in both nuclear and cytoplasmic fractions were 
basically constant during the circadian cycle (Fig. 1B), the subcellular distribution of the CK2 
subunits is not likely to determine the rhythmic kinase activity in the SCN. Importantly, the 
peaks of CK2α-mediated phosphorylation of BMAL1 are at CT10 and CT22. These 
remarkably correlate with the circadian hyperphosphorylation of BMAL1 in vivo and with the 
accumulation of BMAL1 in the cytoplasm before nuclear entry (Fig. 1A and Supplementary 
Fig. 3). These findings suggest that CK2α-mediated rhythmic phosphorylation of BMAL1 
determines its cyclic nuclear entry.  
The physiological role of CK2α in the mammalian circadian clock was assessed by 
microRNAi (miR)-mediated silencing in dexamethazone (Dex)-treated NIH-3T3 fibroblasts. 
Using a specific miR-CK2α silencing vector with a transfection efficacy of about 40-60% (not 
shown) (Fig. 1C), CK2α expression was significantly reduced 48h post-transfection (Fig. 1C). 
To assess the effect of CK2α silencing on clock rhythmicity, we used a mPer2 
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promoter-driven luciferase reporter and monitored real time bioluminescence as previously 
reported 10. Silencing of CK2α resulted in a drastic impairment of circadian Per2 oscillation, 
as compared to cells transfected with the negative control-silencing vector (Fig. 1D). Indeed, 
after a first peak with significantly reduced mPer2 expression, miR-CK2α transfected cells 
showed no subsequent circadian oscillation (Fig. 1D). The reason of this severe effect is likely 
to be ascribed to an aberrant BMAL1 intracellular localization. In fact, cells transfected with 
the control-silencing vector show a prominent nuclear localization of BMAL1 24h after Dex 
treatment, as expected 11. Instead, silencing of CK2α results in a substantial retention of 
BMAL1 in the cytoplasm (Fig. 1E). These results are in keeping with the observation that, 
following cytoplasmic accumulation at ~16h, BMAL1 accumulates in the nucleus 20-24h 
after cells are Dex-treated (not shown) or serum-shocked 11. Finally, treatment of 
serum-shocked cells with the CK2-specific inhibitor D-ribofuranosylbenzimidazole (DRB) 
caused cytoplasmic BMAL1 accumulation (Supplementary Fig. 4). This effect is circadian 
time-dependent, as it is observed only during the period when BMAL1 proteins, which have 
been accumulating in the cytoplasm, enter the nucleus (16-20h post serum-shock) 11. As the 
function of the CLOCK-BMAL1 complex is totally dependent on the nuclear translocation of 
BMAL112, we reason that this is how CK2 exerts its control on the mammalian circadian 
clock. This role is reminiscent of the one observed in Drosophila by dCK2 in regulating the 
nuclear entry of dPER 7.    
To establish the in vivo relevance of CK2α-mediated phosphorylation of BMAL1, we 
sought to identify the CK2 phosphoacceptor target site(s) in BMAL1 and determine its 
function in circadian rhythmicity. By MALDI-TOF/MS analysis we identified a likely 
phosphorylation site at position Ser90 (Fig. 2A). In this assay BMAL1 was highly 
phosphorylated at Ser90 by CK2α, while our results do not exclude the presence of other 
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minor phosphoacceptor site(s). Importantly, Ser90 is highly conserved among all vertebrate 
BMAL1s (Fig. 2B) and is embedded within an amino acid sequence that corresponds to a 
CK2 phosphorylation consensus site consisting of a Serine/Threonine residue with an acidic 
residue at the +3 position (S/T-X-X-D/E). Interestingly, while Ser90 is not conserved in the 
Drosophila counterpart of BMAL1, dCYCLE (not shown), consistent with the notion that 
dCK2α is unable of phosphorylating dCYCLE 7. Thus, it would seem that the mode by which 
CK2 regulates the circadian machinery is different in mammals versus the fly. Finally, Ser90 
is located near to the nuclear localization signal (NLS; Fig. 2B) 13, underscoring the possibility 
of a direct control of nucleocytoplasmic localization of BMAL1 by phosphorylation (see Fig. 
1E). 
    Next, we wanted to establish the role of Ser90 phosphorylation in circadian function. 
To do so, we used mouse embryonic fibroblasts (MEFs) derived from Bmal1-null mice. 
Ablation of BMAL1 in these cells results in a dysfunctional circadian clock and arrhythmic 
gene expression 10,14. Rescue experiments were performed by infecting Bmal1-/- MEFs with 
retroviruses expressing either wild-type BMAL1 (BMAL1-WT), a BMAL1-S90A mutant or 
GFP (Supplementary Fig. 5). Infected MEFs were synchronized by Dex treatment and 
circadian oscillation was monitored by a real-time bioluminescence assay using mPer2 
promoter-driven luciferase reporter vector. Infection of Bmal1-/- MEFs with a virus expressing 
BMAL1-WT rescued circadian mPer2 expression, whereas the BMAL1-S90A mutant was 
unable to do so and generated lower mPer2 expression. These results strongly suggest that 
BMAL1 phosphorylation by CK2α at Ser90 is essential for circadian gene expression (Fig. 
2C).  
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Importantly, the ectopically expressed BMAL1-WT accumulated in the nucleus 24h 
after Dex treatment, an appropriate circadian time that reflects what normally occurs with 
native BMAL1 in NIH-3T3 cells and MEFs 11. On the other hand, the BMAL1-S90A mutant 
remained mostly cytoplasmic (Fig. 2D). Similarly CLOCK, whose intracellular localization 
pattern matches BMAL1 12, could not accumulate in the nucleus when coexpressed with 
BMAL1-S90A (not shown). These data nicely fit the change in the pattern of BMAL1 
localization upon CK2α silencing (Fig. 1E), and stress the notion that circadian function 
requires phosphorylation of BMAL1 and its nuclear accumulation. 
   Our findings demonstrate that CK2α is a circadian rhythmic BMAL1 kinase that plays 
an essential role in the mammalian clock. CK2α-mediated phosphorylation of BMAL1 
appears to constitute an important step for BMAL1 nuclear entry that timely follows its 
accumulation in the cytoplasm. Indeed, DRB-induced cytoplasmic BMAL1 retention occurs 
only during the period when cytoplasmic accumulated BMAL1 proteins normally enter the 
nucleus (Supplementary Fig. 4). While it is likely that CK2 influences circadian physiology at 
multiple levels because it phosphorylates a large array of cellular proteins 15, the remarkable 
specificity observed here on BMAL1-Ser90 provides a lead to further investigations. Finally, 
as BMAL1 has been recently shown to be SUMOylated and acetylated 10,14, we believe that 
the regulatory pathway presented here constitutes a valuable gateway to future investigations 
aimed at unraveling the interplay between phosphorylation and other post-translational 
modifications of clock proteins.  
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Figure Legends 
 
Figure 1 
Circadian rhythmic kinase CK2α is a mammalian clock component that controls 
BMAL1 nuclear entry. 
A) Nuclear (N) and cytoplasmic (C) fractions of rat SCN from each circadian time (n=8) were 
subjected to CK2α-immunoprecipitation for BMAL1 kinase assay and immunoblotting. 
Arrows designate nonphosphorylated forms while bars designate phosphorylated forms.  
B) Immunoblotting for the CK2 subunits. C) NIH-3T3 cells expressing mPer2 
promoter-luciferase reporter were transfected (TF) with microRNAi (miR) targeting vector 
and the negative control vector, then treated with dexametazone (Dex). Lysates were subjected 
to immunoblotting. D) mPer2 promoter activities were monitored by a real time 
bioluminescence assay. E) The miR-transfected GFP-positive cells at 24h post Dex treatment 
were stained with anti-BMAL1. Nuclei were stained with DAPI. The values of nuclear 
BMAL1-dominant cells in the GFP-positive cells are plotted as means + SEM. (***; P < 
0.001). 
  
Figure 2 
The Ser90 CK2 phosphorylation site in BMAL1 is essential for circadian rhythmicity 
and controls BMAL1 nuclear entry.   
A) BMAL1 phosphorylation site(s) by CK2α was determined by MALDI-Tof/MS analysis. 
The arrow indicates the peak corresponding to Ser90-phosphorylation. B) The sequence 
alignment of BMAL1 around the CK2α-phosphorylation target Ser from various species is 
shown. C) mPer2 promoter activities of Bmal1-/- MEFs expressing Myc-BMAL1-WT (wild 
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type), Myc-BMAL1-S90A (Ser90-deficient mutant) and Myc-GFP (control) were monitored 
by a real time bioluminescence assay. D) MEFs at 24h post Dex treatment were stained with 
anti-BMAL1 antibody. Nuclei were stained with DAPI. The values of nuclear 
BMAL1-dominant cells are plotted as means + SEM (***; P < 0.001). 
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(Supplementary figure legends) 
 
S 1. Circadian periodically fluctuating kinase, p45PFK is CK2α.  
A: The 2D-gel electrophoresis pattern for purified p45PFK. p45PFK was purified as described 
previously 9. The concentrated samples were subjected to 2D-electrphoresis with or without 
Histone H1 in the SDSPAGE-gel. The Histone H1-containing gel was subjected to in gel 
kinase assay. The gel was subjected to silver staining. The gel containing Histone H1 
phosphorylating activity (surrounded in the figure) was excised for the microsequencing 
analysis using Mass spectrometry. B: Amino acid sequences of rat, human and Drosophila 
CK2α. Deduced amino acid sequences by MS analysis are shown as red-colored letters.  
 
S 2. Purified p45PFK phosphorylates BMAL1. 
Purified p45PFK was subjected to in vitro kinase assay using GST-BMAL1 as a substrate. 
Proteins were resolved on SDS-PAGE, and the gels were visualized with CBB-staining and 
autoradiography. Purified p45PFK did not phosphorylate GST, as shown previously 9. 
 
S 3. Phosphorylation of BMAL1 protein in the rat SCN.  
Rat SCN from CT10 (n=4) was separated into nuclear (Nucleus) and cytoplasmic (Cytoplasm) 
fractions. +λPPase; aliquots of the samples (20 μg protein) were treated with λ protein 
phosphatase, and then subjected to immunoblot analysis using anti-BMAL1 antibody. The 
phosphorylated (bar) and unphosphorylated (arrow) forms of proteins are indicated.  
 
S 4. Circadian time dependent suppression of BMAL1 nuclear entry by CK2 inhibitor.  
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Serum shocked NIH-3T3 cells were treated with CK2 inhibitor (20 μM DRB) and control 
(DMSO) at 12-16h, 16-20h and 26-30h post serum shock. The cells were 
immunocytochemically stained with anti-BMAL1 (Green). Nuclei were stained with DAPI 
(Blue). 
 
S5. Equivalent levels of ectopically expressed BMAL1 proteins in MEFs. 
Total cell extracts from MEFs stably expressing mBmal1 promoter-driven Myc-BMAL1-WT, 
Myc-BMAL1-S90A (CK2 major phosphorylation site-deficient mutant) and 
CMV-promoter-driven Myc-GFP (as control) were subjected to immunoblot analysis detected 
by anti-Myc antibody. 
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Supplementary methods 
 
Kinase assay, immunoprecipitation, immunoblot and immunocytochemistry 
In gel and in vitro kinase assay were performed as described previously 8, using redivue 
[γ-32P] ATP (Amersham, Japan). Kinase activities were visualized as artificial colors showing 
the intensity as a red to blue color gradient with red as higher intensity, which was analyzed 
with a BAS2000 imager (Fuiji film). Histone-H1 (Boehringer Mannheim, Japan), purified 
p45PFK 9, CK2α, Sf9 cells-produced GST-mBMAL1 (full-length) was prepared according to 
the manufacturer’s protocol (Baculo Gold transfection system; Pharmingen, USA), E-Coli 
produced GST and GST-mBMAL1 were prepared as described previously 9. CK2α was 
prepared by excising CK2α portion from GST-CK2α using Precision protease (Amersham, 
Japan).  
   Immunoprecipitation (using 100μg protein from the rat SCN), immunoblot (using 10μg 
protein) and immunocytochemistry were performed as described previously 11, using 
anti-BMAL1 11, Histone H1, Actin (Santa Cruz. Biotech., USA), Myc-tag (Upstate 
Biotechnology, USA), HRP-conjugated anti-rabbit IgG (Zymed, USA), Alexa Fluor 
564/488-conjugated anti-rabbit IgG and DAPI (Molecular probes, USA). Our previously 
produced anti-BMAL1 antibody 11 detected BMAL1-immunoreactivity specifically in 
BMAL1-expressed cells whereas not in mouse embryonic fibroblasts from Bmal1-null mice 
(Bmal1-/- MEFs) (data not shown). 
 
Microsequencing and determination of the phosphorylation site  
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Purification of p45PFK from rat brain was performed as described previously 9. The 
concentrated samples were subjected to 2D-electrphoresis with or without Histone H1 in the 
SDSPAGE-gel. The Hisotne H1-containing gel was subjected to in gel kinase assay as 
described previously 8. Another gel was subjected to silver staining. The gel portion 
containing Histone H1 phosphorylating activity (surrounded in Supplementary Fig. 1) was 
excised for the microsequencing analysis using Mass spectrometry (MS). 
   GST-mBMAL1 was purified from E.coli, BL21 (Amercham, JAPAN) transformed with 
pGEX-6P-mBMAL1b (full length), which was kindly donated by Chika Nishio (Osaka 
University). GST-mBMAL1 (75pmol) was phosphorylated by CK2α (37.5pmol) after alkaline 
phosphatase treatment. This reaction was performed under the optimal kinase:substrate ratio, 
which was pre-determined (data not shown). BMAL1 phosphorylation site by CK2α was 
determined by MALDI-Tof/MS analysis using Voyager System according to the 
manufacturer’s protocol  (Applied Biosystems, JAPAN). 
  
Preparation of the SCN extracts   Male Wistar rats aged 5-8 weeks were were maintained 
at 25 oC on a 12 h light and 12 h dark cycle for at least 1 week before use. Animals were 
decapitated at each experimental circadian time (CT) point. The SCN region was punched out 
with a 2mm-diameter needle as described previously 8.  Nuclear and cytoplasmic fractions at 
the indicated time points were prepared as described previously 8.  
 
Plasmid construction 
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The vector, pcDNA6.3-GW/EmGFP-miR-CK2α for gene silencing study with microRNAi for 
mouse CK2α knock down was constructed according to the manufacturer’s protocol  
(Invitrogene, JAPAN) using following target sequence.  
Top strand; 
5’-TGCTGTTCTGTTCCCAGAACCTTGGCGTTTTGGCCACTGACTGACGCC 
AAGGTTGGGAACAGAA -3’ 
Bottom Strand; 
5’-CCTGTTCTGTTCCCAACCTTGGCGTCAGTCAGTGGCCAAAACGCCAAGGTTCT 
GGGAACAGAAC -3’ 
   The vector, pGL4-Per2, was constructed to express 1.7kb mPer2 promoter–driven 
destabilized luciferase reporter. E.coli expression vector for GST-CK2α was constructed by 
inserting of PCR products of full-length hCK2α ORF to the C-terminal of GST sequence in 
pGEX-6p vector (Amersham, Japan).   
   Retroviral expression vector (pCLNCX) for Bmal1 promoter-driven Myc-BMAL1 was 
generated as previously described 10,14.  The CK2 major phosphorylation site-deficient 
BMAL1 mutant, S90A was generated with exchanging Ser90 to Ala in mBMAL1b by using 
the QuickChange site-directed mutagenesis (Stratagene, USA). 
 
Cell culture, transfection and retroviral infection 
NIH-3T3 cells and MEFs were cultured as described previously 11. For clock synchronization, 
cells were treated with 0.1μM Dexamethazone for 2h. DNA transfection was performed using 
Fugene 6 and Fugene HD (Roche, Japan) according to the manufacturer’s protocol. RetroMax 
expression system (IMGENEX, USA) was used to produce retrovirus according to 
manufacturer’s protocol. For infection, Bmal1-/- MEFs, which is kindly donated by 
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Christopher A. Bradfield (University of Wisconsin, USA), were incubated with viral solution 
for 3h and this procedure was repeated 4 times. As the results, nearly 100% Bmal1-/- MEFs 
was rescued with mBmal1 promoter-driven Myc-BMAL1 wild type and the mutant (S90A) or 
CMV-promoter-driven Myc-GFP as the negative control.  
 
Real-time bioluminescence assay 
Cells were transfected with plasmids in 10% FBS/DMEM on 35mm dishes. 24h after the 
transfection, cells were treated with 0.1μM Dexamethazone for 2h. Real time bioluminescence 
activities were monitored using Kronos (ATTO, Japan) after changing medium to 
20%FBS/DMEM containing 0.1mM Luciferin and 25mM Hepes, pH7.2. 
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Figure-2 Sassone-Corsi.
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Supplementary Figure-2 Sassone-Corsi
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Supplementary Figure-3 Sassone-Corsi
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Supplementary Figure-4 Sassone-Corsi
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Supplementary Figure- 5 Sassone-Corsi
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